Invicta Diagnostic Limited announced that its subsidiary, Porteus Medical LLP, has incorporated a new entity named Porteus Pathogenius LLP as a step-down subsidiary. The incorporation, executed through an Initial LLP Agreement on 12 June, 2026, aims to expand the group's business operations in diagnostics and pathology services.

Porteus Medical LLP holds a 51% partnership interest in the newly formed entity, contributing an initial capital of ₹51,000. The total capital contribution for Porteus Pathogenius LLP is ₹1,00,000. Consequently, Porteus Pathogenius LLP has become a step-down subsidiary of Invicta Diagnostic Limited. The transaction does not qualify as a related party transaction, as no promoter or group company holds direct interest beyond the indirect control through Porteus Medical LLP.

The newly incorporated LLP will operate in the healthcare, diagnostics, and pathology services sectors. While the entity is yet to commence business operations, it has been established to undertake laboratory and healthcare services. No specific governmental or regulatory approvals were required for the incorporation, apart from those necessary in the ordinary course of business.

Key Details of Porteus Pathogenius LLP

The acquisition is considered complete with the execution of the Initial LLP Agreement. The cost of acquisition for the 51% stake is ₹51,000, acquired at par. The development is part of the company's strategy to broaden its service offerings in the healthcare sector.

Invicta Diagnostic Limited announced on June 1, 2026, that its subsidiary, Porteus Medical LLP, has incorporated a new entity named Porteus Pathogenius LLP. Consequently, Porteus Pathogenius LLP has become a step-down subsidiary of Invicta Diagnostic Limited. The incorporation aims to expand the group's business operations in the healthcare and diagnostics sector.

Porteus Medical LLP has acquired a 51% partnership interest in the newly formed entity by contributing an initial capital of ₹51,000. The total initial capital contribution for Porteus Pathogenius LLP is ₹1,00,000. The transaction does not fall within the ambit of a related party transaction, as neither the promoter group nor other group companies hold any direct interest in the new LLP, apart from the indirect control exercised through Porteus Medical LLP.

The new step-down subsidiary will undertake the business of diagnostics, pathology, healthcare services, and laboratory services. As the entity has been newly incorporated, its current turnover is nil, and it is yet to commence business operations. The initial Limited Liability Partnership (LLP) Agreement is yet to be executed by the partners.

No specific governmental or regulatory approvals are required for the incorporation, other than those necessary in the ordinary course of business. The indicative time period for the completion of the acquisition is one month. The cost of acquisition for the 51% partnership interest is ₹51,000, acquired at par.

Key Details of Porteus Pathogenius LLP